Top

Published in:

Open Access 01-12-2024 | SCLC | Research

Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study

Authors: Boyu Qin, Lingli Xin, Chen Liang, Lingling Li, Qi Song, Yaping Long, Xiaoling Zhang, Dan Wang, Weiwei Shi, Jing Zhang, Yi Hu, Bo Yang, Qi Xiong

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Immunotherapy targeting PD-1/PD-L1 has revolutionized the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, clinical trials suggest differential efficacy of anti-PD-1 agents and anti-PD-L1 agents in first-line treatment of ES-SCLC. This retrospective multicenter study aimed to compare the efficacy and safety of anti-PD-1 agents versus anti-PD-L1 agents in first-line treatment of ES-SCLC in real-world practice.

Methods

Patients with pathologically or cytologically confirmed ES-SCLC treated with platinum plus etoposide combined with anti-PD-1 or PD-L1 agents as first-line treatment in different centers of PLA General Hospital between January 2017 and October 2021 were included for this study. Survival outcomes and safety were compared between patients receiving anti-PD-1 and PD-L1 agents.

Results

Of the total 154 included patients, 68 received anti-PD-1 agents plus chemotherapy (PD-1 group), and 86 received anti-PD-L1 agents plus chemotherapy (PD-L1 group). Progression-free survival (PFS) and overall survival (OS) in the entire cohort were 7.6 months (95% confidence interval [CI]: 6.5–8.2 months) and 17.4 months (95% CI: 15.3–19.3 months), respectively. Median PFS and OS were comparable between the PD-1 group and PD-L1 group (PFS: 7.6 months vs. 8.3 months, HR = 1.13, 95% CI: 0.79–1.62, p = 0.415; OS: 26.9 months vs. 25.6 months, HR = 0.96, 95% CI: 0.63–1.47, p = 0.859. The objective response rate and disease control rate were comparable between the two groups: 79.4% vs. 79.1% and 92.6% vs. 94.2%, respectively. The 6-month, 12-month, and 18-month PFS and OS rates were slightly higher in the PD-L1 group than in the PD-1 group, while the 24-month PFS rate was slightly higher in the PD-1 group than in the PD-L1 group. Stratified analysis showed that locoregional thoracic radiotherapy and normal lactate dehydrogenase level were independent predictors of better OS in ES-SCLC patients treated with first-line chemotherapy plus ICI. Adverse events were not significantly different between the two groups.

Conclusions

Anti-PD-1 agents and anti-PD-L1 agents combined with chemotherapy as first-line treatment for ES-SCLC are comparably effective and well tolerated.

Available only for authorised users

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: a cancer journal for clinicians. 2022;72:7–33. https://doi.org/10.3322/caac.21708

Saltos A, Shafique M, Chiappori A. Update on the biology, management, and treatment of small cell lung cancer (SCLC). Front Oncol. 2020;10:1074. https://doi.org/10.3389/fonc.2020.01074CrossRefPubMedPubMedCentral

Karachaliou N, Pilotto S, Lazzari C, Bria E, de Marinis F, Rosell R. Cellular and molecular biology of small cell lung cancer: an overview. Transl Lung Cancer Res. 2016;5:2–15. https://doi.org/10.3978/j.issn.2218-6751.2016.01.02CrossRefPubMedPubMedCentral

Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104–10. https://doi.org/10.1038/ng.2396CrossRefPubMedPubMedCentral

Ready N, Farago AF, de Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019;14:237–44. https://doi.org/10.1016/j.jtho.2018.10.003CrossRefPubMed

Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, Piperdi B, Mehnert JM. Pembrolizumab in patients with extensive-stage small-cell Lung Cancer: results from the phase ib KEYNOTE-028 study. J Clin Oncol. 2017;35:3823–9. https://doi.org/10.1200/JCO.2017.72.5069CrossRefPubMed

Sequist L, Chiang A, Gilbert J, et al. Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC). Ann Oncol. 2016;27:vi493.CrossRef

Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21:15–25. https://doi.org/10.1038/cdd.2013.67CrossRefPubMed

Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–39. https://doi.org/10.1016/S0140-6736(19)32222-6CrossRefPubMed

10.

Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9. https://doi.org/10.1056/NEJMoa1809064CrossRefPubMed

11.

Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51–65. https://doi.org/10.1016/S1470-2045(20)30539-8CrossRefPubMed

12.

Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739–47. https://doi.org/10.1016/s1470-2045(22)00224-8CrossRefPubMed

13.

Owonikoko T, Kim H, Govindan R, et al. Nivolumab (Nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): results from the double-blind, randomized phase III CheckMate 451 study. Ann Oncol. 2019;30:ii77.CrossRef

14.

Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38:2369–79. https://doi.org/10.1200/jco.20.00793CrossRefPubMedPubMedCentral

15.

Cheng Y, Han L, Wu L, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA: The Journal of the American Medical Association. 2022;328:1223–32. https://doi.org/10.1001/jama.2022.16464CrossRefPubMed

16.

Yu H, Chen P, Cai X, Chen C, Zhang X, He L, Zhou Y, Hong S, Zhang B. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer. Cancer Immunol Immunother. 2022;71:637–44. https://doi.org/10.1007/s00262-021-03017-zCrossRefPubMed

17.

Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33:e213. https://doi.org/10.3346/jkms.2018.33.e213CrossRefPubMedPubMedCentral

18.

Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7. https://doi.org/10.1038/nature14011CrossRefPubMedPubMedCentral

19.

Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Investig. 2015;125:3384–91. https://doi.org/10.1172/jci80011CrossRefPubMedPubMedCentral

20.

Addeo A, Banna GL, Metro G, Di Maio M. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis. Front Oncol. 2019;9:264. https://doi.org/10.3389/fonc.2019.00264CrossRefPubMedPubMedCentral

21.

Wang Z, Zhao J, Ma Z, et al. A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients. Lung Cancer. 2020;147:259–68. https://doi.org/10.1016/j.lungcan.2020.06.007CrossRefPubMed

22.

Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). J Thorac Oncol. 2018;13:1393–9. https://doi.org/10.1016/j.jtho.2018.05.002CrossRefPubMedPubMedCentral

23.

Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15:618–27. https://doi.org/10.1016/j.jtho.2019.12.109CrossRefPubMed

24.

Pujol JL, Greillier L, Audigier-Valette C, et al. A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 Trial. J Thorac Oncol. 2019;14:903–13. https://doi.org/10.1016/j.jtho.2019.01.008CrossRefPubMed

25.

Goldman JW, Dowlati A, Antonia SJ, et al. Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC). J Clin Oncol. 2018;36:8518. https://doi.org/10.1200/JCO.2018.36.15_suppl.8518CrossRef

26.

Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(). Ann Oncol. 2021;32:631–41. https://doi.org/10.1016/j.annonc.2021.01.071CrossRefPubMed

27.

Wu JJ, Huang JW, Hsu KH, Huang YH, Chen KC, Tseng JS, Yang TY, Chang GC. Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy. Anticancer Drugs. 2022;33:e842–e9. https://doi.org/10.1097/cad.0000000000001374CrossRefPubMed

28.

Palma DA, Warner A, Louie AV, Senan S, Slotman B, Rodrigues GB. Thoracic radiotherapy for extensive stage small-cell lung cancer: a meta-analysis. Clin Lung Cancer. 2016;17:239–44. https://doi.org/10.1016/j.cllc.2015.09.007CrossRefPubMed

29.

Tian Y, Ma J, Jing X, Zhai X, Li Y, Guo Z, Yu J, Zhu H. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy. Cancer Lett. 2022;541:215719. https://doi.org/10.1016/j.canlet.2022.215719CrossRefPubMed

30.

Lim JU, Kang HS, Shin AY, Yeo CD, Kim SK, Kim JW, Kim SJ, Lee SH. Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment. Thorac Cancer. 2022;13:3384–92. https://doi.org/10.1111/1759-7714.14697CrossRefPubMedPubMedCentral

31.

Warner AB, Postow MA. Bigger is not always better: tumor size and prognosis in advanced melanoma. Clin cancer Research: Official J Am Association Cancer Res. 2018;24:4915–7. https://doi.org/10.1158/1078-0432.Ccr-18-1311CrossRef

32.

DiBonaventura MD, Shah-Manek B, Higginbottom K, Penrod JR, Yuan Y. Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan. Ther Clin Risk Manag. 2019;15:355–66. https://doi.org/10.2147/tcrm.S183216CrossRefPubMedPubMedCentral

33.

Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619–30. https://doi.org/10.1200/JCO.20.01055CrossRefPubMedPubMedCentral

Title: Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study
Authors: Boyu Qin
Lingli Xin
Chen Liang
Lingling Li
Qi Song
Yaping Long
Xiaoling Zhang
Dan Wang
Weiwei Shi
Jing Zhang
Yi Hu
Bo Yang
Qi Xiong
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: SCLC
SCLC
Radiotherapy
Lung Cancer
Lung Cancer
Lung Cancer
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-11833-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

A preliminary study of IgG4 expression and its prognostic significance in oral squamous cell carcinoma

Epithelial-to-mesenchymal transition and NF-kB pathways are promoted by a mutant form of DDB2, unable to bind PCNA, in UV-damaged human cells

Prevalence of genital high-risk human papillomavirus infections and associated factors among women living with human immunodeficiency virus in Uganda

Prediction model based on MRI morphological features for distinguishing benign and malignant thyroid nodules

Bioelectrical impedance analysis—derived phase angle (PhA) in lung cancer patients: a systematic review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer